Dr Rambaldi speaks with ecancertv at ASH 2016 about the final results of the Northern Italy Leukaemia Group (NILG) trial combining paediatric-type therapy with minimal residual disease (MRD) review, and risk-oriented haematopoietic cell transplantation (HCT) in adult acute lymphoblastic leukaemia (ALL).

The current paediatric-type therapy and MRD-based risk-oriented strategy was applicable to adults with ALL in a wide age range, with some limitations in patients over 60 years.

MRD was essential in orientating the HCT choice in both standard risk and high risk patients and retained a major prognostic role in all patients.

Optimizing the early MRD response with new immunotherapeutics and clarifying the role of HCT in MRD responsive very high risk patients are topics for future research.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.